Project description
3D cell-matrix model for diabetes drug discovery
The demand for diabetes drugs keeps increasing as adult diabetes prevalence is estimated to have risen to 629 million by 2045. There is an urgent need for more effective diabetes medications, which is complicated by the poor predictability of current models in the identification of lead compounds during drug discovery. The EU-funded Cells in Matrix project is developing the 'engineered micro pancreas' (EMP), a 3D model for the R&D of diabetes drugs. It is based on an organ-derived 3D cell culture and human insulin-producing cells and will offer acceleration and cost reduction in diabetes drug development. The EMP system offers extended shelf life and function for in-depth studies on drug molecules' mode of action, validation, toxicology and in vitro pharmacokinetics, enabling higher predictability and reliability.
Objective
The demand for diabetes drugs keeps increasing as adult Diabetes prevalence reached 425 million people in 2017 (1 in 11 adults) and is estimated to rise to 629 million till 2045. The market of Diabetes drugs is expected to reach €80.5 Billion in 2019 while the investment in Diabetes drug development is ~ €4 Billion (CAGR of 13%). There is a constant need for more effective diabetes medications, hampered by the poor predictability of the current systems for identification of lead compounds during drug discovery. The failure rate of new drugs development is about 90% and the cost for reaching the
market with a new drug is ~ €1 Billion.
Cells in Matrix Project develops an innovative 3D model for R&D of Diabetes Drugs , an Engineered Micro Pancreas (EMP) based on organ-derived 3D cell culture and human sourced insulin producing cells as an innovative tool for accelerating and cost reduction of Diabetes drug development. EMP system offers significantly extended shelf life and function for in-depth studies of drug molecules mode of action, validation, toxicology and in vitro pharmacokinetics, rendering higher prediction reliability.
Cells in Matrix disruptive technology creates market added value to all the stakeholders, especially pharma industry, by improving compound screening at least X4 (from 5% rate of success today to at least 20%), resulting in cost saving that could reach €100 million per innovative new drug development.
The project receives strong interest from stakeholders and plans immediate commercialization of the product to direct endusers, including academia and pharma companies, such as Boehringer Ingelheim.
The FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery market. Betalin Therapeutics and Kugelmeiers, the project commercial leading partners will share the growth and revenues gained by its commercial success.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- medical and health sciencesbasic medicinetoxicology
Programme(s)
Funding Scheme
IA - Innovation actionCoordinator
5268101 Ramat Gam
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.